Go to JCI Insight
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
  • Clinical Research and Public Health
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Gastroenterology
    • Immunology
    • Metabolism
    • Nephrology
    • Neuroscience
    • Oncology
    • Pulmonology
    • Vascular biology
    • All ...
  • Videos
    • ASCI Milestone Awards
    • Video Abstracts
    • Conversations with Giants in Medicine
  • Reviews
    • View all reviews ...
    • Clinical innovation and scientific progress in GLP-1 medicine (Nov 2025)
    • Pancreatic Cancer (Jul 2025)
    • Complement Biology and Therapeutics (May 2025)
    • Evolving insights into MASLD and MASH pathogenesis and treatment (Apr 2025)
    • Microbiome in Health and Disease (Feb 2025)
    • Substance Use Disorders (Oct 2024)
    • Clonal Hematopoiesis (Oct 2024)
    • View all review series ...
  • Viewpoint
  • Collections
    • In-Press Preview
    • Clinical Research and Public Health
    • Research Letters
    • Letters to the Editor
    • Editorials
    • Commentaries
    • Editor's notes
    • Reviews
    • Viewpoints
    • 100th anniversary
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • Reviews
  • Review series
  • ASCI Milestone Awards
  • Video Abstracts
  • Conversations with Giants in Medicine
  • In-Press Preview
  • Clinical Research and Public Health
  • Research Letters
  • Letters to the Editor
  • Editorials
  • Commentaries
  • Editor's notes
  • Reviews
  • Viewpoints
  • 100th anniversary
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
Rare codons capacitate Kras-driven de novo tumorigenesis
Nicole L.K. Pershing, Benjamin L. Lampson, Jason A. Belsky, Erin Kaltenbrun, David M. MacAlpine, Christopher M. Counter
Nicole L.K. Pershing, Benjamin L. Lampson, Jason A. Belsky, Erin Kaltenbrun, David M. MacAlpine, Christopher M. Counter
View: Text | PDF
Research Article Oncology

Rare codons capacitate Kras-driven de novo tumorigenesis

  • Text
  • PDF
Abstract

The KRAS gene is commonly mutated in human cancers, rendering the encoded small GTPase constitutively active and oncogenic. This gene has the unusual feature of being enriched for rare codons, which limit protein expression. Here, to determine the effect of the rare codon bias of the KRAS gene on de novo tumorigenesis, we introduced synonymous mutations that converted rare codons into common codons in exon 3 of the Kras gene in mice. Compared with control animals, mice with at least 1 copy of this Krasex3op allele had fewer tumors following carcinogen exposure, and this allele was mutated less often, with weaker oncogenic mutations in these tumors. This reduction in tumorigenesis was attributable to higher expression of the Krasex3op allele, which induced growth arrest when oncogenic and exhibited tumor-suppressive activity when not mutated. Together, our data indicate that the inherent rare codon bias of KRAS plays an integral role in tumorigenesis.

Authors

Nicole L.K. Pershing, Benjamin L. Lampson, Jason A. Belsky, Erin Kaltenbrun, David M. MacAlpine, Christopher M. Counter

×

Figure 1

Generation and characterization of the Krasex3op allele.

Options: View larger image (or click on image) Download as PowerPoint
Generation and characterization of the Krasex3op allele.
(A) Immunoblot ...
(A) Immunoblot reveals changing rare codons to common codons in exon 3 increases ectopic KRAS expression (1 of 2 experiments using cells independently transduced with expression vectors). (B) Position of synonymous mutations (red) in Krasex3op aligned to Krasnat within exon 3. Lowercase letters denote nucleotides from exon 2. (C) Sliding window of codon usage index demonstrating the relative codon usage of the mouse Ras genes including the engineered enrichment of common codons in exon 3 of Krasex3op (red) relative to Krasnat (gray). Theoretical Kras transcripts encoded by all common (red dotted line) or all rare (black dotted line) are plotted for reference. (D) Targeting strategy to change codon usage in exon 3 of Kras. Arrows indicate PCR primers used for genotyping. (E) Representative genotyping from mice with Krasnat and/or Krasex3op alleles used in all genotyping experiments. (F) Semiquantitative RT-PCR analysis revealed similar levels of Kras splice forms 4a and 4b in MEFs isolated from Krasex3op/ex3op versus those from Krasnat/nat mice (1 of 2 experiments using independently derived MEFs). (G) Representative example and quantification (mean ± SEM) of immunoblots revealed higher levels of KRAS protein in lysates of MEFs isolated from Krasex3op/ex3op than levels detected in Krasnat/nat mice (1 of 2 experiments using independently-derived MEFs). (H) Representative example and quantification (mean ± SEM) of immunoblots revealed higher levels of KRAS protein in total lung lysates isolated from Krasex3op/ex3op mice than those detected in Krasnat/nat mice. Comparisons were made using lysates from a total of 16 Krasex3op/ex3op versus 16 Krasnat/nat mice.

Copyright © 2026 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)

Sign up for email alerts